CASI Pharmaceuticals Inc. (NASDAQ:CASI)

Cellectar (NASDAQ: CLRB) Jumps 35% on Expansion of Phase 2 Trial

Cellectar Biosciences (NASDAQ: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces that the company will increase the targeted patient enrollment in the relapsed/refractory (R/R) multiple myeloma (MM) cohort of its currently enrolling Phase 2 clinical trial of CLR 131. Data from the MM cohort of the study demonstrated that the treatment exceeded pre-specified criteria for clinically meaningful benefit. As a result, the cohort will be expanded up to as many as 40 patients.

About the Phase 2 Study of CLR 131
The Phase 2 study is being conducted in approximately 10 leading cancer centers in the United States for patients with relapsed or refractory B-cell hematologic cancers.

About CLR 131
Cellectar (CLRB) developed CLR 131 as an investigational compound under development for a range of orphan designated cancers. It is currently being evaluated as a single-dose treatment in a Phase I clinical trial in patients with R/R MM as well as in a Phase II clinical trial for R/R MM and select R/R lymphomas with either a one- or two-dose treatment. Based upon preclinical and interim Phase I study data, treatment with CLR 131 provides a novel approach to treating solid and hematological tumors and may provide patients with therapeutic benefits, including overall survival, an improvement in progression-free survival, surrogate efficacy marker response rate, and overall quality of life.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CLRB and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Eleven Biotherapeutics Inc (NASDAQ:EBIO)

Eleven Biotherapeutics Inc (NASDAQ:EBIO) Reports Q3 Earnings

Eleven Biotherapeutics Inc (NASDAQ:EBIO)

Eleven Biotherapeutics Inc (NASDAQ:EBIO) shares dropped over 7%, on heavy volume, after the biotech company reported their Q3 2017 financial results. EBIO shares opened at $0.74, then dropped to a low of $0.64 before closing at $0.69. At current levels, EBIO shares are trading below their published cash per share value of $0.71, and their book value per share figure of $1.05.

Eleven Biotherapeutics Inc (NASDAQ:EBIO)

Eleven Biotherapeutics Inc (NASDAQ:EBIO) is a late-stage, clinical oncology company that develops therapies for cancer patients based upon the company’s proprietary targeted protein therapeutics (TPTs) platform. The company’s TPTs incorporate a tumor-targeting antibody fragment and a cytotoxic protein payload within a single protein molecule in order to achieve focused tumor cell killing. Eleven Biotherapeutics believes its TPT approach offers significant advantages in treating cancer over existing antibody drug conjugate technologies. Eleven Biotherapeutics promotes the idea that its TPTs provide effective tumor targeting with broader cancer cell-killing properties than generally achievable other treatments that require tumor cell proliferation to be effective and can face challenges overcoming multi-drug resistance mechanisms within tumor cells.

In November, Eleven Biotherapeutics Inc (NASDAQ:EBIO) completed a public offering of 5,525,000 shares of its common stock, pre-funded warrants to purchase an aggregate of 4,475,000 shares of common stock, and common warrants to purchase up to an aggregate of 10,000,000 shares of common stock, raising approximately $8.0 million in gross proceeds and $7.0 million in net proceeds.

Eleven Biotherapeutics Q3 Earnings

Eleven Biotherapeutics Inc (NASDAQ:EBIO) did not record any revenue for Q3 2017. In Q3 2016, the company reported revenue of $28.7 million. This difference was due to revenue recognized in 2016 from the company’s license agreement with Roche. Roche’s next licensing milestone payment will be triggered upon commencement of a Phase 2 clinical trial by Roche.

Net loss for Q3 2017 was (-$9.1) million, or (-$0.37) per share, versus net income of $19.5 million, or $0.95 per basic share and $0.91 per diluted share, for the same period in 2016. The change was primarily the result of revenue recognized in 2016 from the company’s license agreement with Roche.

Research and development expenses were $3.6 million, compared to $2.8 million for the same period in 2016. Cash and cash equivalents were $11.3 million.

EBIO Stock Performance

Per share earnings for the biotech company have been on an upward trend ever since 2013, when the company reported a loss of (-$16.19). Losses contracted annually and in 2016 a EPS profit of $0.01 was posted. Last year, due to the Roche licensing agreement, the company reported some sales of $30 million. A number that that could be considered “material” for the first time in its existence. However, the company has a consistent history of diluting shareholder equity. In 2013 the number of outstanding shares stood at 1.35 million, then continued to expand on an annual basis. In 2016 the company ended the year with 21.08 million shares outstanding.

For the year, EBIO shares have lost 70%, and, for the month, the shares have lost 45% in value. Despite performance that lags the markets, and its sector, EBIO shares are rated “Market Perform” and “Strong Buy” by the two investment firms that follow the company. Their consensus, one-year price target is $12.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $EBIO and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Aptose Biosciences Inc (NASDAQ:APTO)

New High for Aptose Biosciences Inc (NASDAQ:APTO)

Aptose Biosciences Inc (NASDAQ:APTO)

Aptose Biosciences Inc (NASDAQ:APTO) shares have hit a new 52-week high, are up over 17%, and trading around the $2 handle in mid-afternoon trading. Volume is heavy for the biotech’s shares as they are trading about seven times their daily average.

Aptose Biosciences Inc (NASDAQ:APTO)

Aptose Biosciences Inc (NASDAQ:APTO) is scheduled to be releasing their Q3 2017 earnings report tomorrow, November 14, 2017, after the close of trading. According to Zacks Investment Research, the consensus of analysts are expecting an EPS loss of (-$0.13) per share.

Canadian-based Aptose Biosciences Inc (NASDAQ:APTO) is a clinical-stage biotechnology company committed that develops personalized therapies designed to address unmet medical needs in cancer patients. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer treatment. The company’s pipeline of small molecule cancer therapeutics includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.

APTO Stock Performance

Shareholders of Aptose Biosciences Inc (NASDAQ:APTO) have experienced a good year. Year-to-date, APTO stock is up over 22%, and for the year the gain is an even more impressive 65%. Analysts have given APTO stock a consensus, one-year price target of $3.15. The stock’s 52-week low was established last April at a price of $0.78. Today’s price action, should it hold, will establish a new 52-week high – besting the old mark of $1.79. Given the strong upward momentum of the stock, it is not surprising that the shares have a Relative Strength score of 77 – a level that most traders consider to be a sign of an “overbought” condition.

Aptose Biosciences Inc (NASDAQ:APTO) has no reported sales. Accordingly, their earnings have been negative since 2012. In the past three years, the per share losses have expanded. In 2014 the per share loss was (-$0.53), followed the next year by (-$0.97), and (-$1.15) for 2016.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $APTO and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Agenus Inc. (NASDAQ:AGEN) Unchanged As Q3 Earnings Meet Estimates

Agenus Inc. (NASDAQ:AGEN)

Shares of Agenus Inc. (NASDAQ:AGEN) traded higher, days after the company reported third quarter financial results that met consensus estimates. The stock was up by 0.29% in Thursday’s trading session to end the day at $3.51 a share.

Agenus Inc. (NASDAQ:AGEN)

AGEN Stock Performance

The stock is currently trading in a downtrend after struggling to close above $4.80. For the full year, the stock is down by more than 10%. Agenus Inc. (NASDAQ:AGEN) faces immediate support at $3.40, below which it could drop to a 52-week low of $3.20 a share.

Investor confidence has taken a hit in recent months. It now awaits to be seen if the third quarter financial results will help reinvigorate investor sentiments going forward. For the three months ended September 30, 2017, the immuno-oncology company reported a net loss of (-$36.8) million or (-$0.37) a share, compared to a net loss of (-$40.8) million reported last year.

Net Loss

For the first nine months of the year, Agenus Inc. (NASDAQ:AGEN) reported a net loss of (-$85.7) million compared to a net loss of (-$100.9) million or (-$1.16) a share reported last year. The decrease in net loss was due to the accelerated milestone payment received from Incyte.

Agenus used a total of $26.2 million in operating activities in the quarter, up from $23.8 million used for the corresponding period last year. Cash and cash equivalent as of the end of the quarter totaled $70.1 million compared to $76.4 million as of December, 31, 2016.

Pipeline Development

The developer of immune checkpoint antibodies and cancer vaccines also achieved significant milestones on the development of its pipeline of drugs.

“We are committed to continuing to innovate having generated several first-in-class and best-in-class immuno-oncology agents; our partnering discussions are maturing on multiple fronts and we expect to close on several business development transactions across our portfolio between now and the end of the first quarter of 2018,” said CEO, Garo Armen.

Agenus Inc. (NASDAQ:AGEN) plans to complete a Phase 1 dose-escalation and generate safety and pharmacodynamics data of AGEN1884 in the fourth quarter. It also plans to commence combination trials of AGEN 1884 and AGEN2034 before the end of the year.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AGEN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

New Lows for Curis, Inc. (NASDAQ:CRIS)

Curis, Inc. (NASDAQ:CRIS)

Shares of Curis, Inc. (NASDAQ:CRIS) are down 17.5% after the biotechnology company reported a (-$15.5) million, or (-$0.11) per share, loss on $2.4 million in revenue for Q3 2017. The company’s results were below analyst expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of (-$0.09) cents per share. For the same period last year, Curis reported a net loss of (-$28.3) million, or (-$0.21) per share.

Curis, Inc. (NASDAQ:CRIS)

Curis, Inc. (NASDAQ:CRIS) is a biotechnology company that develops and commercializes drug candidates for the treatment of human cancers, including CUDC-907, which is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis also collaborates with Aurigene in the areas of immuno-oncology and precision oncology. Curis is also in collaboration with biotechnology giant Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma.

CRIS Stock Performance

Shares of Curis, Inc. (NASDAQ:CRIS) hit new 52-week lows, $1.23, after the earnings announcement was released. The 52-week high was established back in November of 2016. However, shares have taken a beating since then and lost over 40% of their value. Year-to-date, CRIS stock performs even worse – down over 50%.

All four investments firms that follow Curis, Inc. (NASDAQ:CRIS) rate CRIS shares as a “Strong Buy” and have a consensus price target of $5.50. This is noteworthy as sales have been in decline for the past five years. In 2012, the company posted sales of $17 million. That figure shrank every year and for 2016 sales were posted at just $7.5 million. On top of the poor sales performance, CRIS shares have had negative earnings for the past five years with the two largest losses coming in 2015 (-$0.48) and 2016 (-$0.46).

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CRIS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Aethlon Medical, Inc. (NASDAQ:AEMD) Partners with iBio Inc.

Aethlon Medical, Inc. (NASDAQ:AEMD)

Aethlon Medical, Inc. (NASDAQ:AEMD) shares fell 3.88% after announcing the formation of a large scale production collaboration agreement with iBio, Inc. (NYSE AMERICAN: IBIO). The primary goal of the collaboration is to advance the large-scale production of Galanthus nivalis agglutinin (GNA), a plant-derived lectin in Aethlon’s Hemopurifier.

Aethlon-iBio Partnership

According to iBio President, Barry Holtz, a collaboration of the two companies is an ideal combination for the delivery of new therapeutic approach for pandemic diseases and biothreats. Researchers from the two companies have already completed a feasibility study that sought to produce highly active recombinant GNA with iBio’s plant technology.

Jim Joyce, Chairman and CEO of Aethlon stated, “The production of recombinant GNA in iBio’s large-scale manufacturing facilities establishes a pathway for us to access a consistent, high-quality supply that can support our long-term clinical and commercialization objectives,”

Aethlon Hemopurifier is a first-class therapeutic device that the U.S. Food and Drugs Administration (FDA) has awarded Expedited Access Pathway for the treatment of life-threatening viruses. The biotechnology company has already validated the device’s ability to capture a broad spectrum of pandemic influenza viruses as well as mosquito-borne viruses and deadly hemorrhagic viruses.

Aethlon Medical, Inc. (NASDAQ:AEMD) is currently investigating the potential use of the Hemopurifier to reduce the presence of tumor-derived exosomes which suppresses immunity and leads to a spread of metastasis in cancer patients.

AEMD Stock Performance

Aethlon Medical, Inc. (NASDAQ:AEMD)

Aethlon’s stock underperformance continued in Monday’s trading session as the stock came under pressure from sellers. The stock is currently trading at multi-year lows after losing more than 70% in market value since the start of the year. The stock dropping below the $1 a share is already arousing concerns about the stock’s continued listing status in the market.

Last week Aethlon Medical, Inc. (NASDAQ:AEMD) issued a statement indicating that the NASDAQ had formally notified it that it complied with all the applicable required listing requirements. While one of the requirements is a $2.5 million stockholder equity position, the share price is also required to be above $1 a share for continued listing

Aethlon Medical, Inc. (NASDAQ:AEMD) is in need of new catalysts if it is to gain favor among investors and bounce back from current trading levels.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AEMD and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

OncoSec Medical Inc. (NASDAQ:ONCS)

OncoSec Medical Inc. (NASDAQ:ONCS) To Make Key Presentations

OncoSec Medical Inc. (NASDAQ:ONCS)

OncoSec Medical Inc. (NASDAQ:ONCS) shares gained 10.1% after the company said it will present updated clinical data on the study of ImmunoPulse IL-12, its lead oncology program. The biotechnology company will make the presentation at the upcoming 9th World Congress of Melanoma.

OncoSec Medical Inc. (NASDAQ:ONCS)

ImmunoPulse IL-12 Presentations

In addition, OncoSec Medical Inc. (NASDAQ:ONCS) is to present updated clinical data from its Phase 2 Investigator Sponsored trial in patients with unresectable metastatic melanoma. The presentation will occur at the upcoming Society for Immunotherapy of Cancer (“SITC”) 32nd Annual Meeting to be held on November 8-12, 2017,

ImmunoPulse IL-12 is a nonviral gene delivery platform designed to utilize the power of the human immune system to target and attack tumors in the body. It is currently in Phase 2 clinical monotherapy trial, for the treatment of stage three and four melanoma.

A presentation by Dr. Alain Algazi will contrast the candidate drug to its combination with pembrolizumab. The presentation will also include clinical and biomarker data from a recently completed Phase 3 monotherapy trial.

“These data, along with the emerging clinical data from the phase 2 combination study, further support the rationale for our global, open-label, registration-directed phase 2b clinical trial, PISCES/KEYNOTE-695, which we anticipate reporting initial data in mid-2018,” said CEO Punit Dhillon.

 ONCS Stock Performance

Investor confidence on OncoSec Medical Inc. (NASDAQ:ONCS) is slowly building following a string of positive news on the development of the company’s lead oncology program. The stock has bounced back from multi-year lows of below $1 a share and bullish momentum continues to grow in strength.

However, the stock is still down by more than 5% for the year after coming under pressure after rising to $1.50 share. OncoSec Medical Incorporated faces immediate resistance at $1.25 a close above which could see the stock making a push for the $1.50 mark.

OncoSec Medical Inc. (NASDAQ:ONCS) has elicited significant investor interest in the recent past as most of them take note of its robust and differentiated approach in developing cancer treatments. The company is currently merging over two decades of research and development processes to accelerate the development of its lead candidate product.

The company’s flagship product, ImmunoPulse IL-12 has already shown to deliver equal gene transmission rates while maintaining a high safety profile. OncoSec Medical Inc. (NASDAQ:ONCS) is advancing the treatment into Phase 2 trials with projected milestone for treatment approval set for 2019.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ONCS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Endocyte, Inc. (NASDAQ:ECYT) Spikes On Prostate Cancer Deal

Endocyte, Inc. (NASDAQ:ECYT)

Endocyte, Inc. (NASDAQ:ECYT) shares gained 0.58% in Tuesday’s trading session as the stock continues to gain significant strength. Renewed investor confidence in the company follows the signing of a licensing deal for a prostate cancer candidate that represents a potential $1 billion market opportunity.

Endocyte, Inc. (NASDAQ:ECYT)

PSMA-617 License

The biopharmaceutical company stock is up by more than 300% for the month as investors continue to react to the exclusive worldwide license for PSMA-617 from ABX GmbH. The deal provides Endocyte with an advanced therapy for the treatment of prostate cancer.

Endocyte, Inc. (NASDAQ:ECYT) is currently rated as a ‘buy’ by one investment firm according to data compiled by Zack Investment Research. One firm also rates the stock as a ‘hold’.

Under the terms of the deal, Endocyte is to make a $12 million upfront payment and issue 2 million shares of its common stock. ABX is also entitled to warrants for the purchase of up to 4 million additional shares. The company could also earn up to $160 million in milestone payments and tiered royalties.

“This transaction is transformational to Endocyte, accelerating our path to commercialization. 177Lu-PSMA-617 has the potential to be the first-in-class RLT to address both bone and soft tissue disease, and it is profoundly important to the many patients suffering from mCRPC,” said Mike Sherman, President, and CEO of Endocyte.

The candidate drug is a radioligand therapeutic, designed to target the prostate-specific membrane antigen that is present in about 80% of patients suffering from metastatic castration-resistant prostate cancer. Endocyte plans to initiate a Phase 3 trial of the drug in the first half of next year with completion slated for 2020.

Endocyte Restructuring

The acquisition of worldwide rights follows the company’s June announcement that the company was focused on more valuable opportunities. A shift of focus into promising programs such as CAR T-cell SMDC adaptor platform has already come into play.

Endocyte, Inc. (NASDAQ:ECYT) is also working on EC1169 for the treatment of metastatic castration-resistant prostate cancer. It has also stopped enrollment in EC1456 trial after the program failed to achieve significant clinical activity necessary for continued advancements.

“Endocyte remains strongly committed to careful expense management and maintaining a strong balance sheet. With the exception of a very targeted effort to generate proof-of-concept data for our CAR T-cell program, we will focus our resources on the development of 177Lu-PSMA-617,” said Mr. Sherman.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ECYT and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

DelMar Pharmaceuticals Inc (NASDAQ:DMPI)

Why Volumes Exploded for DelMar Pharmaceuticals Inc (NASDAQ:DMPI)

DelMar Pharmaceuticals Inc (NASDAQ:DMPI)

Shares of DelMar Pharmaceuticals Inc (NASDAQ:DMPI) are up over 80% after the biopharmaceutical company announced that the U.S. Patent and Trade Office (USPTO) issued a patent covering covering improved analytical methods for analyzing and determining impurities in dianhydrogalactitol (VAL-083). DMPI stock is trading around the $2.00 level after closing at $1.12 yesterday. DelMar Shares gapped up to open at $1,80 before hitting their inter-day high of $2.29. Volumes have been strong. DMPI shares have a 30-day, daily traded volume of under 150,000 but by noon today over 16.8 million shares have traded.

DelMar Pharmaceuticals Inc (NASDAQ:DMPI)
Two day DMPI stock price chart

Delmar Pharmceuticals Patents

The newly issued patent strengthens DelMar Pharmaceuticals Inc (NASDAQ:DMPI) their intellectual property portfolio surrounding their VAL-083 manufacturing process. VAL-083 is billed by DelMar as a first-in-class DNA targeting agent that has successfully demonstrated clinical activity against a range of tumor-types in prior clinical trials sponsored by the U. S. National Cancer Institute (NCI). VAL-083 is currently protected by eight U.S. patents and eight patents outside of the U.S.

DMPI Stock

Ironically, DelMar Pharmaceuticals Inc (NASDAQ:DMPI) was downgraded by Maxim Group just one month ago – from a “Buy” to a “Hold”. DMPI stock had just made a new 52-week low of $1.05 last week. However the news surrounding the patent issuance now places the stock almost 100% off their lows. Unfortunately, long-term holders of DelMar Pharmaceutical stock are still well off their 52-week high of $6.90.

The micro-cap biopharmaceutical firm has only produced a profit for shareholders once in the past five years – in 2014. Per share losses in the other years range from (-$0.46) in 2015 to (-$1.12) in 2013. On top of that, dilution is an ongoing concern for long-term holders of the stock. In 2012 there were 3.31 million shares outstanding. By 2016 that number was reported at 10.95 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DMPI and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

ITUS Corp (NASDAQ:ITUS)

ITUS Corp (NASDAQ:ITUS) Explodes On Cancer Detection Patent

ITUS Corp (NASDAQ:ITUS)

Shares of ITUS Corp (NASDAQ:ITUS) surged 85.15% after the United States Patent and Trademark Office (USPTO) granted the company a patent for an early cancer detection technology. The company’s wholly-owned subsidiary Anixa Diagnostics Corporation is currently developing the technology.

ITUS Corp (NASDAQ:ITUS)
One month ITUS stock price chart

Investor Reaction

Investor reaction does not come as a surprise given what is at stake. Cancer detection and treatment is a multi-billion industry and presents ITUS Corp (NASDAQ:ITUS) a unique opportunity for growth.

The 85.15% rally helped push the stock above the $1.00 per share mark. The stock is still down by more than 60% for the year as it continues to trade in a strong downtrend. A close above the $1.30 mark could see the stock making a run for the $2.00 a share mark which serves a key resistance level. It now awaits to be seen if the new patent will continue to strengthen investor’s sentiments on the stock.

“This is the first patent to issue of several patents that we expect to issue garnering protection of our cancer detection technology. The claims of this patent were allowed in May of 2017, and now we have received the official issuance notification and patent number,” said CEO, Amit Kumar.

Cancer Detection technology

The proposed cancer detection technology utilizes flow cytometer to measure the presence and characteristics of certain circulating immune cells. ITUS Corp (NASDAQ:ITUS) is currently relying on artificial intelligence to analyze data from the immune cells, in a manner that enhances the detection of tumor in patients

The technology has successfully identified 15 types of cancer including breast, prostate, colon, and lung. The technology’s success in detecting various types of cancer is attributed to its ability to measure subtle changes in immune cells.

Itus Corporation has also started to perform additional tests in a bid to evaluate the technology’s ability to detect benign conditions that may exist in patients. The company has since renewed its collaboration with the Wistar Institute for the development of the cancer detection technology. The two have worked together over the last two years.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ITUS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.